Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and
Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's
Disease.
Phase:
Phase 2
Details
Lead Sponsor:
T3D Therapeutics, Inc.
Collaborators:
Alzheimer's Association Clinilabs, Inc. National Institute on Aging (NIA) PRA Health Sciences